Ipsen falls heavily on the stock market after stopping clinical trials
PARIS, January 24 (Reuters) – Ipsen suffers the worst drop in its stock market history Friday after the announcement of the end of clinical trials of an experimental treatment for a rare bone disease, a new setback for the product portfolio in development of the biopharmaceutical group. The Ipsen share lost 21.41% to 65.70 euros … Read more